98%
921
2 minutes
20
Background: Transcranial electrical stimulation (tES) is considered effective and safe for depression, albeit modestly, and prone to logistical burdens when performed in external facilities. Investigation of portable tES (ptES), and potentiation of ptES with remote psychological interventions have shown positive, but preliminary, results.
Research Design: We report the rationale and design of an ongoing multi-arm, randomized, double-blind, sham-controlled clinical trial with digital features, using ptES and internet-based behavioral therapy (iBT) for major depressive disorder (MDD) (NCT04889976).
Methods: We will evaluate the efficacy, safety, tolerability and usability of (1) active ptES + active iBT ('double-active'), (2) active ptES + sham iBT ('ptES-only'), and (3) sham ptES + sham iBT ('double-sham'), in adults with MDD, with a Hamilton Depression Rating Scale - 17 item version (HDRS-17) score ≥ 17 at baseline, during 6 weeks. Antidepressants are allowed in stable doses during the trial.
Results: We primarily co-hypothesize changes in HDRS-17 will be greater in (1) 'double-active' compared to 'ptES-only,' (2) 'double-active' compared to 'double-sham,' and (3) 'ptES-only' compared to 'double-sham.' We aim to enroll 210 patients (70 per arm).
Conclusions: Our results should offer new insights regarding the efficacy and scalability of combined ptES and iBT for MDD, in digital mental health.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627342 | PMC |
http://dx.doi.org/10.1080/14737175.2022.2083959 | DOI Listing |
Stat Methods Med Res
July 2025
Global Biostatistics & Data Sciences, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany.
There is emerging evidence of the increasing uptake of response-adaptive randomization (RAR) in clinical trials. However, a systematic review of RAR trials, their context of use, characteristics, and stakeholder acceptance has been lacking. We performed a systematic review of clinical trials that utilized elements of RAR, identified via the Cortellis Regulatory Intelligence database following a pre-specified selection process.
View Article and Find Full Text PDFCerebrovasc Dis
April 2025
Department of Internal Medicine (Neurology Section), Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Introduction: Adaptive platform trials represent a paradigm shift in stroke research. We examined how patient-partners perceived the design and execution of an international platform trial in acute stroke, ACT-GLOBAL (A multi-faCtorial, mulTi-arm, multi-staGe, randomized, gLOBal Adaptive pLatform trial for stroke), through a series of focus groups with process evaluation methodology.
Methods: Participants were recruited from two comprehensive stroke centers one in Calgary, Canada and one in Sydney, Australia.
Lancet Neurol
April 2025
Neuroscience Research Australia, Sydney, NSW, Australia.
Background: Amyloid plaque removal by monoclonal antibody therapies slows clinical progression in symptomatic Alzheimer's disease; however, the potential for delaying the onset of clinical symptoms in asymptomatic people is unknown. The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) is an ongoing platform trial assessing the safety and efficacy of multiple investigational products in participants with dominantly inherited Alzheimer's disease (DIAD). Based on findings of amyloid removal and downstream biological effects from the gantenerumab group of the platform trial, we continued a 3-year open-label extension (OLE) study to assess the safety and efficacy of long-term treatment with high doses of gantenerumab.
View Article and Find Full Text PDFmedRxiv
January 2025
Neuroscience Research Australia, Sydney, NSW, Australia.
Background: Amyloid-plaque removal by monoclonal antibody therapies slows clinical progression in symptomatic Alzheimer's disease; however, the potential for delaying the onset of clinical symptoms in asymptomatic people is unknown. The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) is an ongoing platform trial assessing the safety and efficacy of multiple investigational products in participants with dominantly inherited Alzheimer's disease (DIAD) caused by mutations. On the basis of findings of amyloid removal and downstream biological effects from the gantenerumab arm of the platform trial, we continued a 3-year open-label extension (OLE) study to assess the safety and efficacy of long-term treatment with high doses of gantenerumab.
View Article and Find Full Text PDFStroke
January 2025
Berry Consultants LLC, Austin, TX (E.L., A.M.C., S.M.B., R.J.L.).
Clinical trials of treatments for stroke have generally utilized 2-arm, randomized designs to evaluate a single intervention against a control. Running separate clinical trials, with each addressing a single therapeutic question, is resource intensive and slows evidence generation, especially in a field with rapidly expanding treatment options and evolving practices. Platform trials-randomized clinical trials designed to evaluate multiple interventions that may enter and exit the ongoing platform based on a master protocol-accelerate the investigation of multiple therapeutic options within a single infrastructure.
View Article and Find Full Text PDF